Phase III
The two trials were evaluating the drug for reducing the rate of moderate-to-severe exacerbations compared to placebo over a 52-week period for inadequately controlled moderate-to-severe asthma (GINA Steps 4 and 5).
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
New findings from the Phase III KEYNOTE-042 Study show improvements in overall survival, progression-free survival and overall response rate in patients treated with Keytruda as a monotherapy.
It missed the primary endpoint by a narrow margin—so narrow, in fact, it comes to about a single patient.
Sanofi believes that sutimlimab, a novel investigational C1s inhibitor, has the potential to be the first approved treatment for cold agglutinin disease, a serious and chronic rare blood disorder.
BioSpace put together a list of the top 10 indications being researched in the area by pharma companies, academic institutions and other organizations.
Bristol-Myers Squibb is looking to start 2020 on the right foot by filing a New Drug Application for its acute myeloid leukemia treatment CC-486 after data shows the medication extends survival time for AML patients.
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, reported positive Phase 3 trial results from the PRIMROSE 2 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids.
Biogen’s plan to seek regulatory approval for aducanumab as a potential new treatment for Alzheimer’s disease is being met with hope for a needed therapy for a dreaded disease, but also some skepticism regarding its long-term efficacy and, ultimately, potential.
PRESS RELEASES